Centric Wealth Management Invests $27,000 in Caribou Biosciences, Inc. (NASDAQ:CRBU)

Centric Wealth Management acquired a new stake in Caribou Biosciences, Inc. (NASDAQ:CRBU) in the 4th quarter, according to its most recent filing with the SEC. The fund acquired 16,847 shares of the company’s stock, valued at approximately $27,000.

A number of other large investors have also bought and sold shares of the business. Erste Asset Management GmbH acquired a new position in Caribou Biosciences in the 3rd quarter worth $28,000. Diametric Capital LP bought a new stake in shares of Caribou Biosciences in the fourth quarter valued at about $42,000. US Bancorp DE boosted its position in shares of Caribou Biosciences by 3,524.2% during the fourth quarter. US Bancorp DE now owns 27,218 shares of the company’s stock worth $43,000 after buying an additional 26,467 shares during the period. Intech Investment Management LLC bought a new position in shares of Caribou Biosciences during the third quarter worth about $43,000. Finally, Thrive Wealth Management LLC acquired a new stake in Caribou Biosciences in the 4th quarter valued at approximately $51,000. 77.51% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have weighed in on CRBU shares. HC Wainwright reaffirmed a “buy” rating and set a $9.00 price target on shares of Caribou Biosciences in a research report on Wednesday, March 19th. Bank of America cut their price objective on shares of Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $10.33.

Caribou Biosciences Stock Down 2.8 %

CRBU stock opened at $0.91 on Tuesday. The company has a market cap of $84.92 million, a price-to-earnings ratio of -0.55 and a beta of 2.34. Caribou Biosciences, Inc. has a twelve month low of $0.88 and a twelve month high of $5.15. The business has a 50 day moving average price of $1.22 and a two-hundred day moving average price of $1.70.

Caribou Biosciences (NASDAQ:CRBU) last released its earnings results on Monday, March 10th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.01. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. The business had revenue of $2.08 million during the quarter, compared to analysts’ expectations of $2.11 million. On average, equities research analysts anticipate that Caribou Biosciences, Inc. will post -1.64 EPS for the current fiscal year.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.